oxldl_u_l sgl

Gender

Visit number vs Plasminogen activator inhibitor-1
N Mean StdDev Median Min Max Unknown Total
Baseline 316 49.2 ± 38.8 37.9 4.3 224.4 2 318
Follow-up 296 47.8 ± 38.3 37.0 2.4 227.2 5 301
Treatment Arm vs Plasminogen activator inhibitor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 316 49.2 ± 38.8 37.9 4.3 224.4 2 318
Healthy Lifestyles and Sleep Education - control arm (HLSE) 106 44.9 ± 34.6 38.2 5.7 196.4 - 106
Healthy Lifestyles and Sleep Education + (supplemental nocturnal) Oxygen - oxygen arm (HLSE-O) 104 51.9 ± 42.5 37.4 5.1 224.4 2 106
Healthy Lifestyles and Sleep Education + Positive airway pressure treatment - CPAP arm (HLSE-P) 106 50.8 ± 39.1 36.7 4.3 155.3 - 106
Treatment Arm vs Plasminogen activator inhibitor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 296 47.8 ± 38.3 37.0 2.4 227.2 5 301
Healthy Lifestyles and Sleep Education - control arm (HLSE) 99 45.5 ± 38.7 34.5 4.7 227.2 1 100
Healthy Lifestyles and Sleep Education + (supplemental nocturnal) Oxygen - oxygen arm (HLSE-O) 100 46.5 ± 35.0 37.2 2.4 156.4 1 101
Healthy Lifestyles and Sleep Education + Positive airway pressure treatment - CPAP arm (HLSE-P) 97 51.6 ± 41.2 40.4 5.4 199.1 3 100
Age category vs Plasminogen activator inhibitor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 316 49.2 ± 38.8 37.9 4.3 224.4 2 318
45-54 years 53 60.7 ± 45.5 49.6 5.7 224.4 - 53
55-64 years 139 50.5 ± 37.3 39.4 5.1 196.4 - 139
65 years or older 124 42.8 ± 36.5 31.0 4.3 162.3 2 126
Age category vs Plasminogen activator inhibitor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 296 47.8 ± 38.3 37.0 2.4 227.2 4 300
45-54 years 47 63.7 ± 41.7 61.1 10.1 199.1 2 49
55-64 years 125 47.4 ± 34.1 42.1 4.7 161.9 2 127
65 years or older 124 42.3 ± 39.6 31.0 2.4 227.2 - 124
Gender of the participant vs Plasminogen activator inhibitor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 316 49.2 ± 38.8 37.9 4.3 224.4 2 318
Female 82 54.6 ± 44.0 42.7 5.9 224.4 2 84
Male 234 47.3 ± 36.8 37.3 4.3 196.4 - 234
Gender of the participant vs Plasminogen activator inhibitor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 296 47.8 ± 38.3 37.0 2.4 227.2 5 301
Female 77 53.8 ± 43.5 43.0 2.4 227.2 2 79
Male 219 45.8 ± 36.2 35.8 5.4 203.5 3 222
Race of the participant vs Plasminogen activator inhibitor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 315 49.3 ± 38.9 38.0 4.3 224.4 2 317
White 256 50.3 ± 39.4 38.6 4.3 224.4 - 256
American Indian or Alaskan Native 2 59.7 ± 5.8 59.7 55.7 63.8 - 2
Black or African American 41 38.1 ± 30.8 25.4 6.9 106.1 2 43
Asian 6 46.6 ± 46.8 31.0 5.7 137.6 - 6
Native Hawaiian or other Pacific islander 1 17.8 - 17.8 17.8 17.8 - 1
Other 4 45.4 ± 36.0 36.7 13.4 94.9 - 4
Multiple 5 94.3 ± 45.9 84.4 30.5 149.0 - 5
Race of the participant vs Plasminogen activator inhibitor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 295 48.0 ± 38.3 37.1 2.4 227.2 4 299
White 238 49.3 ± 39.4 37.7 4.7 227.2 3 241
American Indian or Alaskan Native 2 40.2 ± 10.5 40.2 32.8 47.6 - 2
Black or African American 40 38.7 ± 33.7 31.7 2.4 149.5 1 41
Asian 6 42.2 ± 23.3 43.4 10.1 79.4 - 6
Native Hawaiian or other Pacific islander 1 11.7 - 11.7 11.7 11.7 - 1
Other 3 61.4 ± 18.4 68.7 40.5 74.9 - 3
Multiple 5 67.8 ± 43.3 46.9 31.0 140.2 - 5